Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

News Daily News

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

Michael O'Riordan

September 20, 2024

News Conference News ESC 2024

Stop-or-Not: It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery

Todd Neale

August 30, 2024

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

News Conference News AHA 2021

An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops

Shelley Wood

November 15, 2021

News Conference News SCAI 2018

ORBITA Continues to Surprise: 85% of Sham Arm Opted for PCI When Trial Ended

L.A. McKeown

April 26, 2018

News Daily News

Radial Access Best for PCI Following Thrombolysis in STEMI

Michael O'Riordan

November 27, 2017

News Daily News

Meta-analysis Calls Into Question Strength of Guidance for RAS Blockade in Patients With Stable CAD

Todd Neale

January 19, 2017

News Daily News

Shock’s Added Risk in Acute MI Restricted to the First Few Months After Discharge

Caitlin E. Cox

February 16, 2016

News Industry News

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

August 31, 2015

News Daily News

Indirect Comparisons Show Little Difference Among New Anticoagulants

August 14, 2012

News Daily News

Celecoxib Enhances DES Efficacy, But at Clinical Cost

March 15, 2012

Advertisement

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

Stop-or-Not: It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops

ORBITA Continues to Surprise: 85% of Sham Arm Opted for PCI When Trial Ended

Radial Access Best for PCI Following Thrombolysis in STEMI

Meta-analysis Calls Into Question Strength of Guidance for RAS Blockade in Patients With Stable CAD

Shock’s Added Risk in Acute MI Restricted to the First Few Months After Discharge

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

Indirect Comparisons Show Little Difference Among New Anticoagulants

Celecoxib Enhances DES Efficacy, But at Clinical Cost

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content